



Biocon Limited
20th KM, Hosur Road
Electronic City
Bangalore 560 100, India
T 91 80 2808 2808
F 91 80 2852 3423
CIN : L24234KA1978PLC003417
E: co.secretary@biocon.com

www.biocon.com

BIO/SECL/TG/2026-27/73

October 14, 2026

To The Manager, BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001	To The Manager, National Stock Exchange of India Limited Corporate Communication Department Exchange Plaza, Bandra Kurla Complex Mumbai – 400 051
Scrip Code - 532523	Scrip Symbol - BIOCON

Subject: Company Statement

Dear Sir/Madam,

Please find enclosed Company Statement w.r.t. **“Biocon Secures Earliest Licensed Launch Dates for Pebrilzo® (bPertuzumab) Following Global Patent Settlement with Genentech”**.

The above information will also be available on the website of the Company at www.biocon.com.

Kindly take the same on record and acknowledge.

Thanking You,

Yours faithfully,

For **Biocon Limited**

RAJESH
UMAKANT
SHANOE

Digitally signed by
RAJESH UMAKANT
SHANOE
Date: 2026.10.14 08:23:20
+05'30'

Rajesh U. Shanoy
Company Secretary and Compliance Officer
M. No.: ACS 16328

Encl: Company Statement



NOTIFICATION TO STOCK EXCHANGE

COMPANY STATEMENT

Biocon Secures Earliest Licensed Launch Dates for Pebrilzo® (bPertuzumab) Following Global Patent Settlement with Genentech

BENGALURU, India: October 14, 2026

Biocon Limited (BSE: 532523, NSE: BIOCON) has entered into a global settlement and license agreement with Genentech, securing earliest licensed launch dates for Pebrilzo®, its biosimilar to the reference product Perjeta® (Pertuzumab).

Biocon and Genentech executed the patent settlement agreement to resolve all pending disputes between the companies, including in the U.S., Canada, and other jurisdictions.

This global patent settlement and license agreement enables Biocon to launch Pebrilzo® in Q1 of calendar year (CY) 2027 in the European Union and UK, Q3 of CY 2028 in the U.S., and in CY 2026-2028 in other Rest of the World (RoW) countries or earlier in certain circumstances.

The other terms of the agreement are confidential.

Pebrilzo® is a biosimilar medicinal product and the active substance is Pertuzumab, a monoclonal antibody that binds with high affinity and specificity to the human epidermal growth factor receptor 2 (HER2), inhibiting the proliferation of tumour cells that overexpress HER2. Pebrilzo® is used for the treatment of HER2-positive breast cancer across multiple disease stages.

Note:

- *All trademarks, registered or unregistered, are the property of their respective owners.*
- *Product launches in all the countries/ regions are subject to regulatory approval.*

Forward-Looking Statement: *Statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied. The Company undertakes no obligation to update these statements except as required by law.*